ClinicalTrials.gg
CompletedNCT04281095Updated Jul 9, 2020

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines

A Phase 1/2 interventional study of Botulinum toxin type A in Glabellar Frown Lines, sponsored by ATGC Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by ATGC Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2019, registered Feb 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.

02

Conditions studied

  • Glabellar Frown Lines
03

In context

Lead sponsor

ATGC Co., Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged between 19 to 65 years
  • Subjects assigned a glabellar line severity grade of 2 or greater (moderate) at maximum frown assessed by the Investigator
  • Subjects who provide written consent to voluntarily participate in the study after receiving and understanding a detailed explanation of the study

Exclusion criteria

Exclusion Criteria:

  • Subjects with diseases that may affect neuromuscular function, such as Myasthenia gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis, or motor neuropathy
  • Subjects with the history of eyelid paralysis or ptosis
  • Subjects with significant facial asymmetry
  • Individuals whose glabellar lines cannot be satisfactorily improved with physical methods since lines are not flattened even using hands
  • Subjects who have received medication that inhibits neuromuscular function within the 4 weeks prior to screening such as muscle relaxants, anticholinergics, benzodiazepines and similar drugs, benzamides, tetracycline antibiotics, lincomycin antibiotics, and aminoglycoside antibiotics
  • Subjects taking anticoagulants or antiplatelet agents (Use of low-dose aspirin (325 mg/day or less) to prevent blood clotting is allowed)
  • Subjects who have received aspirin or NSAIDs within 7 days prior to administration of the IP.
  • Subjects with skin abnormalities such as infection at the injection site, dermatopathy, or scars.
  • Subjects with the history of treatment of the glabellar region (including the forehead) such as face lifting, permanent implants, or fillers
  • Subjects who have received other procedures that may affect the assessment of the glabellar or forehead lines during the following periods:

    • Within 6 months of screening: facial plastic surgery such as tissue augmentation, brow lift, or dermal resurfacing.
    • Within 6 months of screening: injection of dermal fillers with hyaluronic acid as the main ingredient.
    • Within 12 months of screening: injection of dermal fillers with ingredients other than hyaluronic acid as the main ingredient.
  • Individuals planning a facial cosmetic procedure (skin fillers, photorejuvenation, chemical/mechanical peeling, etc.) during the study period.
  • Individuals who have received a botulinum toxin preparation within 5 months prior to screening or those who are expected to receive a botulinum toxin preparation for any other purpose than the indication of this study (glabellar lines).
  • Subjects with the history of excessive alcohol consumption or drug addiction
  • Individuals with an anxiety disorder or other significant psychiatric disorders (e.g., depression), which, in the Investigator's opinion, may affect study participation or objective assessment of efficacy outcomes
  • Individuals who answered "yes" to any of the questions on the Columbia University Suicide Severity Rating Scale (C-SSRS) regarding a case within the past 12 months at the screening
  • Female subjects of childbearing age who do not agree to practice using medically allowed contraceptive methods during the study period (hormonal contraception, IUD (intrauterine device) or IUS (intrauterine system), tubal ligation, dual protection (using a combination of male condom, female condom, cervical cap, contraceptive diaphragm, or contraceptive sponge)
  • Pregnant or lactating women
  • Subjects who are allergic or sensitive to the IP or its components
  • Individuals with concomitant illnesses that make them unsuitable for participation in the study by the Investigator such as malignant tumors, immunodeficiency (immune deficiency), kidney disease, liver disease, or lung disease
  • Individuals who have participated in other clinical trials within 3 months prior to participating in this study and have received an IP or medical device during the previous clinical studies
  • Individuals who are not eligible for this study for any reason as per the Investigator's discretion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Botulinum toxin type A(ATGC-110)

    Drug: Botulinum toxin type A

  • Active comparator
    Botulinum toxin type A

    Drug: Botulinum toxin type A

Interventions

  • Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each

06

What researchers measure

Primary outcomes

  1. Glabellar line improvement rate at maximum frown confirmed with investigator's live assessment

    Changes in the glabellar line severity at maximum frown from baseline to 4 weeks after the IP administration were evaluated by investigator

    Time frame: 0 and 4 weeks after the administration

Secondary outcomes

  1. Glabellar line improvement rate at maximum frown confirmed by investigator's live assessment

    Changes in the glabellar line severity at maximum frown from baseline to 8 and 12 weeks after the IP administration were evaluated by investigator

    Time frame: 0, 8, 12 weeks after the administration

  2. Glabellar line improvement rate at rest confirmed by investigator's live assessment

    Changes in the glabellar line severity at rest from baseline to 4, 8 and 12 weeks after the IP administration were evaluated by investigator

    Time frame: 0, 4, 8, 12 weeks after the administration

  3. Glabellar line improvement rate at rest confirmed by subject's assessment

    Changes in the glabellar line severity at rest from baseline to 4, 8 and 12 weeks after the IP administration were evaluated by subjects

    Time frame: 0, 4, 8, 12 weeks after the administration

  4. Subject satisfaction rate

    Subjects fill out the satisfaction questionnaire

    Time frame: 0, 4, 8, 12 weeks after the administration

07

Study locations

1 site
  • Nowon Eulji Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Apr 2020, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Feb 24, 2020
StartActual
Nov 1, 2019
Primary completionActual
Apr 30, 2020
CompletionActual
Apr 30, 2020
Last update
Jul 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04281095
Lead sponsor
ATGC Co., Ltd.
Responsible party
Sponsor
First posted
Feb 24, 2020
Start date
Nov 1, 2019
Primary completion
Apr 30, 2020
Completion
Apr 30, 2020
Last update
Jul 9, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion